Literature DB >> 26370613

Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera.

Jie Bai1, Limei Ai2, Lei Zhang1, Feng-Chun Yang3, Yuan Zhou1, Yanping Xue1.   

Abstract

Post-polycythemia vera myelofibrosis (post-PV MF) is a critical hematologic evolution of polycythemia vera (PV). The main purpose of the present study was to identify the possible risk factors for the occurrence and prognosis of post-PV MF in Chinese patients with PV. A cohort of 272 Chinese PV patients with JAK2(V617F) or exon12 mutation was retrospectively analyzed. Of the 272 patients with PV, 63 developed post-PV MF. Platelet count >550 × 10(9) /L and splenomegaly were identified as independent risk factors for post-PV MF. The median duration of survival for post-PV MF patients was 8 years. Anemia and age >65 years at diagnosis of post-PV MF were identified as significant predictors for the poor prognosis of post-PV MF. In conclusion, platelet counts and splenomegaly were significant predictors for the transformation to post-PV MF, while anemia (hemoglobin levels <100 g/L) and age>65 years were significant predictors for poor prognosis of post-PV MF in Chinese PV patients with JAK2(V617F) or exon12 mutation.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26370613     DOI: 10.1002/ajh.24191

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  7 in total

1.  JAK2 V617F as a Marker for Long-Term Disease Progression and Mortality in Polycythemia Vera and its Role in Economic Modeling.

Authors:  Jonas Hjelmgren; Kristoffer Nilsson; Gunnar Birgegård
Journal:  J Health Econ Outcomes Res       Date:  2020-06-04

2.  The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry.

Authors:  Chris Varghese; Tracey Immanuel; Anna Ruskova; Edward Theakston; Maggie L Kalev-Zylinska
Journal:  Curr Oncol       Date:  2021-04-18       Impact factor: 3.677

Review 3.  Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Manifestations, And Effects On Outcomes.

Authors:  Danielle Cuthbert; Brady Lee Stein
Journal:  J Blood Med       Date:  2019-10-18

4.  Thrombosis among 1537 patients with JAK2V617F -mutated myeloproliferative neoplasms: Risk factors and development of a predictive model.

Authors:  Yuhui Zhang; Yuan Zhou; Yingshao Wang; Guangshuai Teng; Dapeng Li; Yan Wang; Chenxiao Du; Yafang Chen; Huiqin Zhang; Yanqi Li; Lixia Fu; Kangyin Chen; Jie Bai
Journal:  Cancer Med       Date:  2020-01-28       Impact factor: 4.452

5.  Volumetric Splenomegaly in Patients With Polycythemia Vera.

Authors:  Myung-Won Lee; Sang-Hoon Yeon; Hyewon Ryu; Ik-Chan Song; Hyo-Jin Lee; Hwan-Jung Yun; Seon Young Kim; Jeong Eun Lee; Kyung Sook Shin; Deog-Yeon Jo
Journal:  J Korean Med Sci       Date:  2022-03-21       Impact factor: 2.153

Review 6.  Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.

Authors:  S Cerquozzi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-11-13       Impact factor: 11.037

Review 7.  Is there a gender effect in polycythemia vera?

Authors:  Francesca Palandri; Barbara Mora; Naseema Gangat; Lucia Catani
Journal:  Ann Hematol       Date:  2020-10-02       Impact factor: 3.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.